<DOC>
	<DOC>NCT00852631</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally given, up to 600 mg once a day for 42 days.</brief_summary>
	<brief_title>Seroquel XR in Adults With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patient meets the DSMIV criteria for schizophrenia Patient has a PANSS total score ≥ 70 at baseline Patient has a CGIS score of ≥ 4(moderately ill) at baseline Patient is healthy on the basis of physical examination and vital signs at baseline Positive urine drug screen for Opiates, amphetamine, barbiturate, cocaine, cannabis, or ecstasy abuse Has history of neuroleptic malignant syndrome, seropositive for antiHIV, hepatitis B or C virus antigen Patient with unstable or inadequately treated Diabetes Mellitus Use of potent cytochrome P450 inhibitors or inducer within 14 days before baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Quetiapine efficacy in schizophrenia</keyword>
</DOC>